We also observed that mutations in TP53 and TET2 were not detected in de novo AML but presented in sAML and R/R AML, suggesting that these mutations were likely acquired during disease relapse or progression and may influence treatment response and outcomes. Here, TET2 is linked to acute myeloid leukemia.